Sino Biological,Inc. (SHE:301047)
China · Delayed Price · Currency is CNY 159.00
+15.74 (10.99%)
At close: Sep 30, 2026
Sino Biological,Inc. Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 740.02 | 671.3 | 587.29 | 630.95 | 574.6 | 965.27 |
Other Revenue | 27.98 | 28.27 | 26.38 | 15.44 | - | - |
| 768 | 699.56 | 613.67 | 646.39 | 574.6 | 965.27 | |
Revenue Growth | 21.43% | 14.00% | -5.06% | 12.49% | -40.47% | -39.53% |
Cost of Revenue | 204.6 | 190.48 | 170.98 | 125.85 | 95.01 | 68.98 |
Gross Profit | 563.4 | 509.09 | 442.69 | 520.54 | 479.59 | 896.29 |
Selling, General & Admin | 328.3 | 310.79 | 305.19 | 280.26 | 207.29 | 141.48 |
Research & Development | 86.48 | 86.22 | 91.21 | 87.45 | 60.15 | 40.13 |
Other Operating Expenses | 16.05 | 14.98 | 8.74 | 6.03 | 8.36 | 13.45 |
Operating Expenses | 442.78 | 418.88 | 413.4 | 384.78 | 276.06 | 199.74 |
Operating Income | 120.62 | 90.21 | 29.29 | 135.76 | 203.53 | 696.56 |
Interest Expense | -2.58 | -3.09 | -3.98 | -3.73 | -2.77 | -2.01 |
Interest & Investment Income | 43.48 | 67.47 | 103.6 | 136.28 | 129.49 | 54.58 |
Currency Exchange Gain (Loss) | -13.89 | -3.44 | -1.6 | 1.84 | 12.05 | -8.07 |
Other Non Operating Income (Expenses) | -0.23 | -0.32 | -0.62 | -0.45 | -0.4 | -0.63 |
EBT Excluding Unusual Items | 147.41 | 150.84 | 126.7 | 269.71 | 341.9 | 740.43 |
Gain (Loss) on Sale of Investments | 51.96 | 24.63 | 4.88 | 10.98 | -14.38 | 34.14 |
Gain (Loss) on Sale of Assets | 0.15 | 0.54 | -0.35 | 0.05 | 0.21 | -0.01 |
Other Unusual Items | 6.39 | 3.54 | 10.1 | 7.21 | 14.78 | 70.89 |
Pretax Income | 205.91 | 179.54 | 141.33 | 287.95 | 342.51 | 845.45 |
Income Tax Expense | 40.67 | 31.8 | 19.41 | 27.82 | 39.55 | 125.44 |
Net Income | 165.24 | 147.74 | 121.93 | 260.13 | 302.96 | 720.01 |
Net Income to Common | 165.24 | 147.74 | 121.93 | 260.13 | 302.96 | 720.01 |
Net Income Growth | 39.24% | 21.17% | -53.13% | -14.14% | -57.92% | -36.15% |
Shares Outstanding (Basic) | 122 | 122 | 128 | 129 | 114 | 108 |
Shares Outstanding (Diluted) | 122 | 122 | 128 | 129 | 114 | 108 |
Shares Change | -2.35% | -4.93% | -0.97% | 13.44% | 5.79% | 11.11% |
EPS (Basic) | 1.36 | 1.21 | 0.95 | 2.01 | 2.66 | 6.69 |
EPS (Diluted) | 1.36 | 1.21 | 0.95 | 2.01 | 2.66 | 6.69 |
EPS Growth | 42.60% | 27.45% | -52.67% | -24.30% | -60.22% | -42.53% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 71 | 45.14 | 43.78 | -720.8 | 93.34 | 594.72 |
Free Cash Flow Per Share | 0.58 | 0.37 | 0.34 | -5.58 | 0.82 | 5.52 |
Dividend Per Share | 2.200 | 5.200 | 1.000 | 2.000 | 2.000 | 5.263 |
Dividend Growth | -56.00% | 420.00% | -50.00% | 0% | -62.00% | - |
Gross Margin | 73.36% | 72.77% | 72.14% | 80.53% | 83.47% | 92.85% |
Operating Margin | 15.71% | 12.90% | 4.77% | 21.00% | 35.42% | 72.16% |
Profit Margin | 21.52% | 21.12% | 19.87% | 40.24% | 52.73% | 74.59% |
Free Cash Flow Margin | 9.24% | 6.45% | 7.13% | -111.51% | 16.24% | 61.61% |
EBITDA | 183.12 | 155.34 | 94.72 | 182.03 | 221.27 | 708.9 |
EBITDA Margin | 23.84% | 22.20% | 15.44% | 28.16% | 38.51% | 73.44% |
D&A For EBITDA | 62.5 | 65.13 | 65.43 | 46.26 | 17.74 | 12.35 |
EBIT | 120.62 | 90.21 | 29.29 | 135.76 | 203.53 | 696.56 |
EBIT Margin | 15.71% | 12.90% | 4.77% | 21.00% | 35.42% | 72.16% |
Effective Tax Rate | 19.75% | 17.71% | 13.73% | 9.66% | 11.55% | 14.84% |
Revenue as Reported | 768 | 699.56 | 613.67 | 646.39 | 574.6 | 965.27 |
Advertising Expenses | - | 23.53 | 28.18 | 34.43 | 36.95 | 25.14 |